Zepzelca (lurbinectedin) is a licensed oncology product indicated for extensive-stage small cell lung cancer. It is approved by TFDA for first-line maintenance therapy when used in combination with immunotherapy. As a specialized pharmaceutical, it is intended for healthcare institutions and distributors involved in oncology treatment protocols, requiring cold chain logistics and stringent regulatory handling for international sourcing.
Manufactured by Lotus Pharmaceutical, based in Tashkent, Uzbekistan, a company founded in 1966, this product supports the therapeutic management of a specific cancer subtype. Buyers in the pharmaceutical sourcing sector typically evaluate such products based on regulatory clearance, therapeutic indication, and manufacturer track record. This entry represents a registered treatment option within its approved use case, suitable for buyers seeking verified oncology products from Central Asian production facilities.